Overactive Bladder Treatment Market Trends

  • Report ID: 4868
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Overactive Bladder Treatment Market Trends

Growth Drivers

  • Growing Geriatric Population– The elderly population is more prone to age-related changes to the urinary system and bladder which might lead to a rise in the incidence of overactive bladder. Reduced urethral sphincter tone, reduced bladder capacity, and diminished bladder muscular strength are some of the age-related changes observed in older people.
    According to estimates, the number of individuals in the world who are 60 or older will increase to over 2 billion by 2050.
  • Rise in Adoption of Sedentary Lifestyles – The pelvic floor muscles, which are crucial for bladder control, might lose strength and tone as a result of a sedentary lifestyle. Overactive bladder (OAB) symptoms may result from weak pelvic floor muscles.
    Besides this, a sedentary lifestyle may also raise the risk of getting urinary tract infections (UTIs), which could cause or aggravate overactive bladder symptoms in persons of all ages, including young adults.

Challenges

  • High Cost of Treatment– For some people seeking therapy for an overactive bladder, the high expense of care might be a substantial deterrent. OAB treatment may involve a variety of alternatives, each with a different price tag, including dietary changes, prescription drugs, and medical procedures.
    Some therapies used to treat OAB including antimuscarinic pharmaceuticals, may be pricey and need to be used for a long time, which might result in substantial out-of-pocket expenses for patients. In addition, some medical procedures, such as injections of botulinum toxin or sacral nerve stimulation could be expensive and may not be covered by insurance.
  • Limited Patient Awareness
  • Side Effects of Medication

Overactive Bladder Treatment Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

6.7%

Base Year Market Size (2024)

USD 5.17 billion

Forecast Year Market Size (2037)

USD 11.8 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4868
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of overactive bladder treatment is estimated at USD 5.44 billion.

The overactive bladder treatment market size was over USD 5.17 billion in 2024 and is projected to cross USD 11.8 billion by the end of 2037, growing at more than 6.7% CAGR during the forecast period i.e., between 2025-2037. Growing number of pregnancies and the growing inclination toward minimally invasive procedures will boost the market growth.

North America is predicted to account for the largest share of over 40% by 2037, impelled by growing investment in healthcare.

The major players in the market include Astellas Pharma, Inc., Pfizer, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo International Plc., Johnson & Johnson Private Limited, India Medtronic Private Limited, Boston Scientific Corporation, Cognetix Medical, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample